By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 500.39% and ...

Tirzepatide may be more effective than semaglutide in helping people lose weight. At least that's the findings from recent ...

Research backs this up: Young men who consumed more protein while losing weight and on an intense exercise regiment gained ...

Amazon may be known for its retail and tech chops, but the company has also built a strong operation in the healthcare realm over the last several years.

If you’re starting a weight loss journey, you might have stumbled upon tirzepatide — the drug approved by the FDA (U.S. Food ...

Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...

Zepbound and Lilly's widely used diabetes drug, Mounjaro, both chemically called tirzepatide, belong to a class of drugs ...

The U.S. Food and Drug Administration (FDA) announced on Monday the approval of the first generic version of a ...

In a new study, researchers examined the health effects people experienced when they returned to still-standing homes after ...

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO -1.51%) stock ...

CEO's use of Eli Lilly's (LLY) weight loss drug Mounjaro over Novo Nordisk's (NVO) rival product, Ozempic. Read more here.